Comprehensive Analysis of a Novel Lipid Metabolism-Related Gene Signature for Predicting the Prognosis and Immune Landscape in Uterine Corpus Endometrial Carcinoma.

Xiaofang Tan,Liangyu Yao,Guoliang Cui,Jiayi Ding,Shuang Liu,Jinhui Liu,Song Cao

doi:10.1155/2022/8028825

Abstract

Lipid metabolism is important in various cancers. However, the association between lipid metabolism and uterine corpus endometrial carcinoma (UCEC) is still unclear. In this study, we collected clinicopathologic parameters and the expression of lipid metabolism-related genes (LMRGs) from the Cancer Genome Atlas (TCGA). A lipid metabolism-related risk model was built and verified. The risk score was developed based on 11 selected LMRGs. The expression of 11 LMRGs was confirmed by qRT-PCR in clinical samples. We found that the model was an independent prediction factor of UCEC in terms of multivariate analysis. The overall survival (OS) of low-risk group was higher than that in the high-risk group. GSEA revealed that MAPK signaling pathway, ERBB signaling pathway, ECM receptor interaction, WNT pathway, and TGF-β signaling pathway were enriched in the high-risk group. Low-risk group was characterized by high tumor mutation burden (TMB) and showed sensitive response to immunotherapy and chemotherapy. In brief, we built a lipid metabolism gene expression-based risk signature which can reflect the prognosis of UCEC patients and their response to chemotherapeutics and immune therapy.

Highlights

As the second common gynecologic malignancy in women, uterine corpus endometrial carcinoma (UCEC) has 65,620 new cases and 12,590 deaths in USA [1]
different expressed LMRGs (DELMGs) between UCEC Samples and Adjacent Normal Tissues. e brief workflow of this research was exhibited in the Supplementary Figure 1
We obtained 614 lipid metabolism-related genes (LMRGs) for differentially expressed analysis. en, the DELMGs between cancer and normal tissues were screened with our cutoff threshold

Summary

Introduction

As the second common gynecologic malignancy in women, UCEC has 65,620 new cases and 12,590 deaths in USA [1]. In China, the five-year OS rate of UCEC is just over a half [2]. Comparing with the developed countries, China has a gap in the field of the UCEC treatment and survival rate [3]. Cancer survival has improved in the past 50 years except UCEC. Death rates of UCEC increased over the past decade [1, 4]. It is crucial to explore the possible mechanisms of the development of UCEC

Methods

Results

Conclusion